Fulgent Genetics Inc
NASDAQ:FLGT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.71
30.27
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fulgent Genetics Inc
Fulgent Genetics Inc
Accounts Receivables
Fulgent Genetics Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fulgent Genetics Inc
NASDAQ:FLGT
|
Accounts Receivables
$57.3m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Accounts Receivables
$2.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Accounts Receivables
$1.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
CVS Health Corp
NYSE:CVS
|
Accounts Receivables
$9.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-1%
|
|
|
Cigna Corp
NYSE:CI
|
Accounts Receivables
$27.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Accounts Receivables
$2.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
Fulgent Genetics Inc
Glance View
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 645 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.
See Also
What is Fulgent Genetics Inc's Accounts Receivables?
Accounts Receivables
57.3m
USD
Based on the financial report for Sep 30, 2024, Fulgent Genetics Inc's Accounts Receivables amounts to 57.3m USD.
What is Fulgent Genetics Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
60%
Over the last year, the Accounts Receivables growth was 16%. The average annual Accounts Receivables growth rates for Fulgent Genetics Inc have been -22% over the past three years , 60% over the past five years .
You don't have any saved screeners yet
